These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
327 related articles for article (PubMed ID: 12957289)
1. TSC2 regulates VEGF through mTOR-dependent and -independent pathways. Brugarolas JB; Vazquez F; Reddy A; Sellers WR; Kaelin WG Cancer Cell; 2003 Aug; 4(2):147-58. PubMed ID: 12957289 [TBL] [Abstract][Full Text] [Related]
2. Hypoxia-inducible factor 1alpha is regulated by the mammalian target of rapamycin (mTOR) via an mTOR signaling motif. Land SC; Tee AR J Biol Chem; 2007 Jul; 282(28):20534-43. PubMed ID: 17502379 [TBL] [Abstract][Full Text] [Related]
3. Tuberous sclerosis complex tumor suppressor-mediated S6 kinase inhibition by phosphatidylinositide-3-OH kinase is mTOR independent. Jaeschke A; Hartkamp J; Saitoh M; Roworth W; Nobukuni T; Hodges A; Sampson J; Thomas G; Lamb R J Cell Biol; 2002 Oct; 159(2):217-24. PubMed ID: 12403809 [TBL] [Abstract][Full Text] [Related]
4. Pathogenesis of tuberous sclerosis subependymal giant cell astrocytomas: biallelic inactivation of TSC1 or TSC2 leads to mTOR activation. Chan JA; Zhang H; Roberts PS; Jozwiak S; Wieslawa G; Lewin-Kowalik J; Kotulska K; Kwiatkowski DJ J Neuropathol Exp Neurol; 2004 Dec; 63(12):1236-42. PubMed ID: 15624760 [TBL] [Abstract][Full Text] [Related]
5. Suppression of the proliferation of hypoxia-Induced retinal pigment epithelial cell by rapamycin through the /mTOR/HIF-1α/VEGF/ signaling. Liu NN; Zhao N; Cai N IUBMB Life; 2015 Jun; 67(6):446-52. PubMed ID: 25988388 [TBL] [Abstract][Full Text] [Related]
6. A GSK-3/TSC2/mTOR pathway regulates glucose uptake and GLUT1 glucose transporter expression. Buller CL; Loberg RD; Fan MH; Zhu Q; Park JL; Vesely E; Inoki K; Guan KL; Brosius FC Am J Physiol Cell Physiol; 2008 Sep; 295(3):C836-43. PubMed ID: 18650261 [TBL] [Abstract][Full Text] [Related]
7. Regulation of mTOR function in response to hypoxia by REDD1 and the TSC1/TSC2 tumor suppressor complex. Brugarolas J; Lei K; Hurley RL; Manning BD; Reiling JH; Hafen E; Witters LA; Ellisen LW; Kaelin WG Genes Dev; 2004 Dec; 18(23):2893-904. PubMed ID: 15545625 [TBL] [Abstract][Full Text] [Related]
8. Enhanced expression of glucose transporter-1 in vascular smooth muscle cells via the Akt/tuberous sclerosis complex subunit 2 (TSC2)/mammalian target of rapamycin (mTOR)/ribosomal S6 protein kinase (S6K) pathway in experimental renal failure. Lin CY; Hsu SC; Lee HS; Lin SH; Tsai CS; Huang SM; Shih CC; Hsu YJ J Vasc Surg; 2013 Feb; 57(2):475-85. PubMed ID: 23265586 [TBL] [Abstract][Full Text] [Related]
9. Tsc2 null murine neuroepithelial cells are a model for human tuber giant cells, and show activation of an mTOR pathway. Onda H; Crino PB; Zhang H; Murphey RD; Rastelli L; Gould Rothberg BE; Kwiatkowski DJ Mol Cell Neurosci; 2002 Dec; 21(4):561-74. PubMed ID: 12504590 [TBL] [Abstract][Full Text] [Related]
10. Rheb binds tuberous sclerosis complex 2 (TSC2) and promotes S6 kinase activation in a rapamycin- and farnesylation-dependent manner. Castro AF; Rebhun JF; Clark GJ; Quilliam LA J Biol Chem; 2003 Aug; 278(35):32493-6. PubMed ID: 12842888 [TBL] [Abstract][Full Text] [Related]
11. Loss of Tsc1 or Tsc2 induces vascular endothelial growth factor production through mammalian target of rapamycin. El-Hashemite N; Walker V; Zhang H; Kwiatkowski DJ Cancer Res; 2003 Sep; 63(17):5173-7. PubMed ID: 14500340 [TBL] [Abstract][Full Text] [Related]
12. Mammalian target of rapamycin mediates the angiogenic effects of leptin in human hepatic stellate cells. Aleffi S; Navari N; Delogu W; Galastri S; Novo E; Rombouts K; Pinzani M; Parola M; Marra F Am J Physiol Gastrointest Liver Physiol; 2011 Aug; 301(2):G210-9. PubMed ID: 21252047 [TBL] [Abstract][Full Text] [Related]
13. Hypoxia-inducible factor-1alpha polymorphisms and TSC1/2 mutations are complementary in head and neck cancers. Hebert C; Norris K; Parashar P; Ord RA; Nikitakis NG; Sauk JJ Mol Cancer; 2006 Jan; 5():3. PubMed ID: 16412252 [TBL] [Abstract][Full Text] [Related]
14. Efficacy of combined inhibition of mTOR and ERK/MAPK pathways in treating a tuberous sclerosis complex cell model. Mi R; Ma J; Zhang D; Li L; Zhang H J Genet Genomics; 2009 Jun; 36(6):355-61. PubMed ID: 19539245 [TBL] [Abstract][Full Text] [Related]
15. Association of focal adhesion kinase with tuberous sclerosis complex 2 in the regulation of s6 kinase activation and cell growth. Gan B; Yoo Y; Guan JL J Biol Chem; 2006 Dec; 281(49):37321-9. PubMed ID: 17043358 [TBL] [Abstract][Full Text] [Related]
16. Sirolimus inhibits human pancreatic carcinoma cell proliferation by a mechanism linked to the targeting of mTOR/HIF-1 alpha/VEGF signaling. Wang Y; Zhao Q; Ma S; Yang F; Gong Y; Ke C IUBMB Life; 2007 Nov; 59(11):717-21. PubMed ID: 17968710 [TBL] [Abstract][Full Text] [Related]
17. Loss of Tsc1/Tsc2 activates mTOR and disrupts PI3K-Akt signaling through downregulation of PDGFR. Zhang H; Cicchetti G; Onda H; Koon HB; Asrican K; Bajraszewski N; Vazquez F; Carpenter CL; Kwiatkowski DJ J Clin Invest; 2003 Oct; 112(8):1223-33. PubMed ID: 14561707 [TBL] [Abstract][Full Text] [Related]
18. Phosphorylation and functional inactivation of TSC2 by Erk implications for tuberous sclerosis and cancer pathogenesis. Ma L; Chen Z; Erdjument-Bromage H; Tempst P; Pandolfi PP Cell; 2005 Apr; 121(2):179-93. PubMed ID: 15851026 [TBL] [Abstract][Full Text] [Related]
19. Critical role of T-loop and H-motif phosphorylation in the regulation of S6 kinase 1 by the tuberous sclerosis complex. Shah OJ; Hunter T J Biol Chem; 2004 May; 279(20):20816-23. PubMed ID: 14993219 [TBL] [Abstract][Full Text] [Related]